Improving risk assessment: Toxicological research needs

Human and Ecological Risk Assessment

Volumn 8, Issue 6, 2002, Pages 1405-1419

  Toraason, Mark ^a   Andersen, Mel ^b   Bogdanffy, Matthew S ^c   Dankovic, David ^a   Faustman, Elaine ^d   Foster, Paul ^e   Frederick, Clay ^f   Haber, Lynne ^g   Kimmel, Carole A ^h   Lewis, Steven ⁱ   McClellan, Roger ^b   Melnick, Ronald ^j   Mirer, Frank ^k   Morgan, Kevin ^l   Schaeffer, Val ^m   Silbergeld, Ellen ⁿ   Slikker, William ^o   Swenberg, James ^p   Vainio, Harri ^q  

^a NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

^b EI Dupont ^*

^c DUPONT COMPANY   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e CIIT CENTERS FOR HEALTH RESEARCH   (United States)

^f ROHM AND HAAS COMPANY   (United States)

^g Toxicology Excellence for Risk Assessment   (United States)

^h U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

ⁱ EXXONMOBIL UPSTREAM RESEARCH COMPANY   (United States)

^j NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^k International Union   (United States)

^l GLAXOSMITHKLINE   (United States)

^m Occupational Safety and Health Administration   (United States)

ⁿ UNIVERSITY OF MARYLAND   (United States)

^o CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^p UNIVERSITY OF NORTH CAROLINA   (United States)

^q INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

more..

Author keywords

Dose response; Exposure assessment; Genomics; Life stages; Pharmacokinetics; Susceptibility

Indexed keywords

ANIMALIA;

EID: 3242775399     PISSN: 10807039     EISSN: None     Source Type: Journal    
DOI: 10.1080/20028091057439     Document Type: Conference Paper

References (47)

1. Andersen ME, MacNaughton MG, Clewell HJ, et al. 1987. Adjusting exposure limits for long and short exposure periods using a physiological pharmacokinetic model. Am Ind Hyg Assoc J 48: 335-43
2. Andersen ME, Mills JJ, Gargas ML, et al. 1993. Modeling receptor-mediated processes with dioxin: implications for pharmacokinetics and risk assessment. Risk Anal 13:25-36
3. Bosch RJ, Wypij D, and Ryan LM. 1996. A semiparametric approach to risk assessment for quantitative outcomes. Risk Anal 16:657-65
4. Brody LC and Beisecker BB. 1998. Breast cancer susceptablity genes. BRCA1 and BRCA2. Medicine 77:208-26
5. Byczkowski JZ, Gearhart JM, and Fisher JW. 1994. "Occupational" exposure of infants to toxic chemicals via breast milk. Nutrition 10:43-8
6. Chen JJ, Kodell RL, and Gaylor DW. 1996. Risk assessment for nonquantal toxic effects. In: Fan AM and Chang LW (eds), Toxicology and Risk Assessment, pp 503-513. Marcel Dekker, Inc., New York
7. Chien JY, Thummel KE, and Slattery JT. 1997. Pharmacokinetic consequences of induction of CYP2E1 by ligand stabilization. Drug Metab Dispos 25:1165-75
8. Colt JS and Balir A. 1998. Parental occupational exposures and risks of childhood cancer. Environ Health Perspec 106 (Suppl. 3):909-25
9. Crump KS. 1995. Calculation of benchmark doses from continuous data. Risk Anal 15:79-89
10. de Wildt SN, Kearns GL, Leeder JS, et al. 1999. Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet 36:439-52
11. Fasouliotis SJ and Schenker JG. 2000. BRCA1 and BRCA2 gene mutations: Decision-making dilemmas concerning testing and management. Obstet Gynecol Surv 55:373-84
12. Faustman EM, Silbernagel SM, Fenske RA, et al. 2000. Mechanisms underlying children's susceptibility to environmental toxicants. Environ Health Perspec 108 (Suppl 1):13-21
13. Fisher J, Mahle D, Bankston L, et al. 1997. Lactational transfer of volatile chemicals in breast milk. Am Ind Hyg Assoc J 58:425-31
14. Gaylor DW. 1996. Quantalization of continuous data for benchmark dose estimation. Toxicol Pharmacol 24:246-50
15. Gaylor DW, Ryan L, Krewski D, et al. 1998. Procedures for calculating benchmark doses for health risk assessment. Toxicol Pharmacol 28:150-64
16. Gaylor DW and Slikker Jr W. 1990. Risk assessment for neurotoxic effects. Neurol Toxicol 11:211-8
17. Glowa JR and MacPhail RC. 1995. Quantitative approaches to risk assessment in neurotoxicology. In: Chang LW and Slikker Jr W (eds), Neurotoxicology: Approaches and Methods, pp 777-787. Academic Press, San Diego
18. Golub MS. 2000. Adolescent health and the environment. Environ Health Perspect 108, (Suppl 3): 355-62
19. Gowen LC, Avrutskaya AV, Latour AM, et al. 1998. BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 281:1009-12
20. Haber LT, Allen BC, and Kimmel CA. 1998. Non-cancer risk assessment for nickel compounds: issues associated with dose-response modeling of inhalation and oral exposures. Toxicol Sci 43:213-29
21. Hattis D. 1996. Human interindividual variability in susceptibility to toxic effects: From annoying detail to central determinant of risk. Toxicology 111:5-14
22. Ishibe N, Wiencke JK, Zuo ZF, et al. 1997. Susceptibility to lung cancer in light smokers associated with CYP1A1 polymorphisms in Mexican- and African-Americans. Cancer Epidemiol Biomarkers Prev 6:1075-80
23. Jarabek A. 1995. Consideration of temporal toxicity challenges current default assumptions. Inhalation Toxicology 7:927-46
24. Katida M, Kamataki K, Itahashi K, et al. 1985. Purification and properties of cytochrome P-450 from homogenates of human fetal livers. Arch Biochem Biophys 241:275-80
25. Kavlock RJ, Allen BC, Kimmel CA, et al. 1995. Dose-response assessment for developmental toxicity: IV. Benchmark doses for fetal weight changes. Fund Appl Toxicol 26:211-22
26. Kodell RL, Chen JJ, and Gaylor DW. 1995. Neurotoxicity modeling for risk assessment. Toxicology and Pharmacology 22:24-9
27. Leroux BG, Leisenring WM, Moolgavkar SH, et al. 1996. A biologicallybased dose-response model for developmental toxicology. Risk Anal 4:449-58
28. Lovett RA. 2000. Toxicologists brace for genomics revolution. Science 289:536
29. Melnick RL, Huff J, Chou BJ, et al. 1990. Carcinogenicity of 1,3-butadiene in C57BL/6 x C3HF1 mice at low exposure concentrations. Cancer Res 50:6592-9
30. Mollerup S, Ryberg D, Hewer A, et al. 1999. Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients. Cancer Res 59:3317-20
31. Perera FP. 2000. Molecular epidemiology: On the path to prevention? J Nat Cancer Inst 92:602-12
32. Plenge-Bonig A and Karmaus W. 1999. Exposure to toluene in the printing industry is associated with subfecundity in women but not in men. Occup Environ Med 56:443-8
33. Renwick AG and Lazarus NR. 1998. Huamn variability and noncancer risk assessment - an analysis of the default uncertainty factor. Regul Toxicol Pharmacol 27:3-20
34. Renwick RG. 1991. Safety factors and establishment of acceptable daily limits. Food Addit Contam 8:135-50
35. Santostefano MJ, Wang X, Richardson VM, et al. 1998. A pharmacodynamic analysis of TCDD-induced cytochrome P450 expression in multiple tissues: Dose- and time-dependent effects. Toxicol Appl Pharmacol 151:294-310
36. Selevan SG, Kimmel CA, and Mendola P. 2000. Identifying critical windows of exposure for children's health. Environ Health Perspect 108 (Suppl 3):451-5
37. Shuey DL, Lau C, Logsdon TR, et al. 1994. Biologically based dose-response modeling in developmental toxicology: Biochemical and cellular sequelae of 5-fluorouracil exposure in the developing rat. Toxicol Appl Pharmacol 126:129-44
38. Slikker Jr W, Crump KS, Andersen ME, et al. 1996. Biologically based, quantitative risk assessment of neurotoxicants. Fund Appl Toxicol 29:18-30
39. Slikker Jr W, Scallet AC, and Gaylor DW. 1998. Biologically-Based close-response mode for neurotoxicity risk assessment. Toxicol Letters 102-103:429-33
40. Taskinen HK, Kyyronen P, Sallmen M, et al. 1999. Reduced fertility among female wood workers exposed to formaldehyde. Am J Ind Med 36:206-12
41. Tateishi T, Nakura H, Asoh M, et al. 1997. A comparison of hepatic cytochrome P450 protein expression between infancy and postinfancy. Life Sci 61:2567-74
42. Tee LB, Gilmore KS, Meyer D, et al. 1992. Expression of glutathione S-transferase during rat liver development. Biochem J 282:209-18
43. Trizna Z, de Andrade M, Kyritsis AP, et al. 1998. Genetic polymorphisms in glutathione S-transferase and, N-acetyltransferase, and CYP1A1 and risk of gliomas. Cancer Epidemiol Biomark Prev 7:553-5
44. USEPA (U.S. Environmental Protection Agency). 1998. Methods for derivation of inhalation reference concentrations and application of inhalation dosimetry. EPA-600/8-90-066. Health Committee of the Science Advisory Board, Washington, DC, USA
45. Waring JF and Urlich RG. 2000. The impact of genomics-based technologies on drug safety evaluation. Ann Rev Toxicol 40:335-52
46. Weller E, Long N, Smith A, et al. 1999. Dose-rate effects of ethylene oxide exposure on developmental toxicity. Toxicol Sci 50:259-70
47. Wrighton SA, Molowa DT, and Guzelian PS. 1988. Identification of a cytochrome P-450 in human fetal liver related to glucocorticoid-inducible cytochrome P-450HLp in the adult. Biochem Pharmacol 37:3053-5